Catalog No.S1888 Synonyms: MDL 458
Molecular Weight(MW): 441.52
Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.|
|In vivo||Deflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats.  Deflazacort reduces thymus weight and Daily weight gain in rats. Deflazacort lowers liver IFG-I and GHR mRNA in rats.  Deflazacort (DFC) is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. Deflazacort and [3H]dexamethasone (DEX) similarly induce in vivo ornithine decarboxylase activity in hippocampus and liver, although body weight loss after chronic treatment is significantly less for DFC.  Deflazacort induces dose-dependent decreases in osteocalcin (OC) plasma production rate (PPR). Deflazacort and prednisolone increase both postabsorptive plasma glucose and plasma calcium levels in sheep, but there are no significant differences between their effects.  Deflazacort, especially combined with L-arginine, spares quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise. Deflazacort alone prevents the typical progressive loss of function (measured as voluntary distance run over 24 hours) that is observed 3 months later in placebo-treated mice.  Deflazacort causes a less significant alteration in the pattern of GH secretion and does not negatively affect the overall amount of GH secreted. |
-  Jeong I, et al. Neuropharmacology,?012, 62(7), 2261-2266.
-  Latta K, et al. Eur J Endocrinol,?994, 131(6), 652-657.
-  Coirini H, et al. J Steroid Biochem Mol Biol, 1994, 49(1), 43-49.
|In vitro||DMSO||88 mg/mL (199.31 mM)|
|Ethanol||12 mg/mL (27.17 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03783923||Recruiting||Drug: Deflazacort|Drug: Placebo||Limb-Girdle Muscular Dystrophy||PTC Therapeutics||May 15 2019||Phase 3|
|NCT03642145||Withdrawn||Drug: Deflazacort||Duchenne Muscular Dystrophy||PTC Therapeutics||October 31 2018||Phase 3|
|NCT02251600||Completed||Drug: Deflazacort||Duchenne Muscular Dystrophy||PTC Therapeutics||December 2014||Phase 1|
|NCT02286622||Completed||Drug: Deflazacort||Renal Impairment||PTC Therapeutics||December 2014||Phase 1|
|NCT02286609||Completed||Drug: Deflazacort||Hepatic Impairment||PTC Therapeutics||December 2014||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.